Scroll

vilazodone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4223	163521-12-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: vilazodone viibryd vilazodone hydrochloride vilazodone HCl	A benzofuran, indole, and piperazine derivative that functions as a SEROTONIN UPTAKE INHIBITOR and partial SEROTONIN 5-HT1 RECEPTOR AGONIST. It is used as an ANTIDEPRESSIVE AGENT. Molecular weight: 441.54 Formula: C26H27N5O2 CLOGP: 4.33 LIPINSKI: 0 HAC: 7 HDO: 2 TPSA: 102.29 ALOGS: -3.56 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

vilazodone
viibryd
vilazodone hydrochloride
vilazodone HCl

A benzofuran, indole, and piperazine derivative that functions as a SEROTONIN UPTAKE INHIBITOR and partial SEROTONIN 5-HT1 RECEPTOR AGONIST. It is used as an ANTIDEPRESSIVE AGENT.

Molecular weight: 441.54
Formula: C26H27N5O2
CLOGP: 4.33
LIPINSKI: 0
HAC: 7
HDO: 2
TPSA: 102.29
ALOGS: -3.56
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	4.85 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	3.76 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.03 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	15.66 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 21, 2011	FDA	FOREST LABS LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Suicidal ideation	243.18	20.93	117	5103	55268	50544636
Abnormal dreams	136.69	20.93	47	5173	9330	50590574
Hallucination	122.63	20.93	70	5150	46587	50553317
Persistent genital arousal disorder	99.78	20.93	18	5202	234	50599670
Serotonin syndrome	89.80	20.93	46	5174	24667	50575237
Sleep paralysis	74.88	20.93	16	5204	516	50599388
Nightmare	73.48	20.93	35	5185	16051	50583853
Agitation	72.73	20.93	53	5167	53331	50546573
Anxiety	72.08	20.93	90	5130	177516	50422388
Paraesthesia	70.94	20.93	74	5146	120169	50479735
Mania	59.97	20.93	27	5193	10889	50589015
Insomnia	57.57	20.93	80	5140	174785	50425119
Suicide attempt	46.03	20.93	40	5180	51692	50548212
Anger	43.78	20.93	22	5198	11311	50588593
Completed suicide	42.85	20.93	60	5160	131829	50468075
Feeling abnormal	42.13	20.93	58	5162	125434	50474470
Crying	41.51	20.93	26	5194	20390	50579514
Seizure	40.35	20.93	55	5165	117819	50482085
Dizziness	40.10	20.93	101	5119	346268	50253636
Tremor	39.91	20.93	54	5166	114849	50485055
Depression	32.69	20.93	60	5160	165363	50434541
Muscle twitching	32.24	20.93	20	5200	15411	50584493
Sleep terror	29.48	20.93	8	5212	715	50599189
Irritability	29.43	20.93	24	5196	28402	50571502
Panic attack	28.13	20.93	20	5200	19322	50580582
Withdrawal syndrome	27.47	20.93	19	5201	17571	50582333
Diarrhoea	24.94	20.93	123	5097	588353	50011551
Nausea	24.83	20.93	140	5080	705258	49894646
Hypnagogic hallucination	24.47	20.93	5	5215	129	50599775
Tardive dyskinesia	22.02	20.93	12	5208	7267	50592637
Electric shock sensation	21.47	20.93	5	5215	240	50599664

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Serotonin syndrome	143.93	32.05	50	1758	17462	29555257
Suicidal ideation	143.57	32.05	60	1748	34656	29538063
Completed suicide	91.97	32.05	61	1747	90185	29482534
Mania	53.26	32.05	20	1788	8643	29564076
Sexual dysfunction	49.18	32.05	17	1791	5797	29566922
Anxiety	39.01	32.05	36	1772	85329	29487390
Overdose	37.12	32.05	34	1774	79785	29492934

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Suicidal ideation	206.78	22.67	101	4834	66441	64427356
Serotonin syndrome	141.30	22.67	66	4869	39216	64454581
Completed suicide	106.77	22.67	107	4828	224307	64269490
Persistent genital arousal disorder	98.82	22.67	17	4918	228	64493569
Abnormal dreams	83.55	22.67	31	4904	10325	64483472
Anxiety	75.62	22.67	85	4850	202564	64291233
Hallucination	67.72	22.67	51	4884	72737	64421060
Mania	60.46	22.67	28	4907	16258	64477539
Sleep paralysis	55.72	22.67	12	4923	546	64493251
Paraesthesia	54.55	22.67	59	4876	134463	64359334
Anger	52.08	22.67	25	4910	15716	64478081
Insomnia	51.10	22.67	69	4866	197767	64296030
Nightmare	50.86	22.67	27	4908	20966	64472831
Tremor	48.22	22.67	58	4877	148172	64345625
Crying	46.32	22.67	25	4910	20065	64473732
Agitation	39.78	22.67	41	4894	88326	64405471
Irritability	39.23	22.67	28	4907	36718	64457079
Intentional overdose	39.17	22.67	41	4894	89903	64403894
Suicide attempt	37.61	22.67	36	4899	70971	64422826
Off label use	35.13	22.67	117	4818	632689	63861108
Muscle twitching	33.92	22.67	20	4915	18978	64474819
Memory impairment	30.26	22.67	35	4900	85647	64408150
Feeling abnormal	29.11	22.67	43	4892	133559	64360238
Dizziness	24.19	22.67	80	4855	430083	64063714
Seizure	23.30	22.67	44	4891	166848	64326949

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N06AX24	NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Other antidepressants
MeSH PA	D000928	Antidepressive Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D058825	Serotonin 5-HT1 Receptor Agonists
MeSH PA	D018490	Serotonin Agents
MeSH PA	D017366	Serotonin Receptor Agonists
MeSH PA	D017367	Serotonin Uptake Inhibitors
CHEBI has role	CHEBI:35469	antidepressants
CHEBI has role	CHEBI:35941	serotonin agonists
CHEBI has role	CHEBI:50949	SSRI

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Major depressive disorder	indication	370143000
Suicidal thoughts	contraindication	6471006
Bipolar disorder	contraindication	13746004	DOID:3312
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Syndrome of inappropriate vasopressin secretion	contraindication	55004003	DOID:3401
Blood coagulation disorder	contraindication	64779008	DOID:1247
Hyponatremia	contraindication	89627008
Seizure disorder	contraindication	128613002
Suicidal	contraindication	267073005
Serotonin syndrome	contraindication	371089000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.56	acidic
pKa2	13.13	acidic
pKa3	8.58	Basic
pKa4	1.41	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
10MG	VIIBRYD	ALLERGAN	N022567	Jan. 21, 2011	RX	TABLET	ORAL	7834020	June 5, 2022	TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG	VIIBRYD	ALLERGAN	N022567	Jan. 21, 2011	RX	TABLET	ORAL	8193195	June 5, 2022	TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG	VIIBRYD	ALLERGAN	N022567	Jan. 21, 2011	RX	TABLET	ORAL	8236804	June 5, 2022	TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG	VIIBRYD	ALLERGAN	N022567	Jan. 21, 2011	RX	TABLET	ORAL	7834020	June 5, 2022	TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG	VIIBRYD	ALLERGAN	N022567	Jan. 21, 2011	RX	TABLET	ORAL	8193195	June 5, 2022	TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG	VIIBRYD	ALLERGAN	N022567	Jan. 21, 2011	RX	TABLET	ORAL	8236804	June 5, 2022	TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
40MG	VIIBRYD	ALLERGAN	N022567	Jan. 21, 2011	RX	TABLET	ORAL	7834020	June 5, 2022	TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
40MG	VIIBRYD	ALLERGAN	N022567	Jan. 21, 2011	RX	TABLET	ORAL	8193195	June 5, 2022	TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
40MG	VIIBRYD	ALLERGAN	N022567	Jan. 21, 2011	RX	TABLET	ORAL	8236804	June 5, 2022	TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
10MG	VIIBRYD	ALLERGAN	N022567	Jan. 21, 2011	RX	TABLET	ORAL	Jan. 31, 2023	INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS AGES 7 TO 17 YEARS OF AGE WITH MAJOR DEPRESSIVE DISORDER
20MG	VIIBRYD	ALLERGAN	N022567	Jan. 21, 2011	RX	TABLET	ORAL	Jan. 31, 2023	INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS AGES 7 TO 17 YEARS OF AGE WITH MAJOR DEPRESSIVE DISORDER
40MG	VIIBRYD	ALLERGAN	N022567	Jan. 21, 2011	RX	TABLET	ORAL	Jan. 31, 2023	INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS AGES 7 TO 17 YEARS OF AGE WITH MAJOR DEPRESSIVE DISORDER
10MG	VIIBRYD	ALLERGAN	N022567	Jan. 21, 2011	RX	TABLET	ORAL	July 31, 2023	PEDIATRIC EXCLUSIVITY
20MG	VIIBRYD	ALLERGAN	N022567	Jan. 21, 2011	RX	TABLET	ORAL	July 31, 2023	PEDIATRIC EXCLUSIVITY
40MG	VIIBRYD	ALLERGAN	N022567	Jan. 21, 2011	RX	TABLET	ORAL	July 31, 2023	PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN	INHIBITOR	IC50	9.30	IUPHAR	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN	AGONIST	Ki	9.70	IUPHAR	CHEMBL
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN	AGONIST	IC50	7.15	IUPHAR
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN	AGONIST	IC50	6.50	IUPHAR
5-hydroxytryptamine receptor 4	GPCR	Q13639	5HT4R_HUMAN	AGONIST	IC50	6.60	IUPHAR
Adrenergic receptor alpha-2	GPCR	P08913 P18089 P18825	ADA2A_HUMAN ADA2B_HUMAN ADA2C_HUMAN		IC50	5.22	CHEMBL
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	AGONIST	IC50	6.18	IUPHAR
Adrenergic receptor alpha-1	GPCR	P25100 P35348 P35368	ADA1D_HUMAN ADA1A_HUMAN ADA1B_HUMAN		IC50	5.70	CHEMBL
5-hydroxytryptamine receptor 7	GPCR	P34969	5HT7R_HUMAN		Ki	5.41	CHEMBL
5-hydroxytryptamine receptor 1B	GPCR		5HT1B_RAT		IC50	5.30	CHEMBL
D(2) dopamine receptor	GPCR		DRD2_RAT		IC50	6.18	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		IC50	9.52	CHEMBL
Sodium-dependent serotonin transporter	Transporter		SC6A4_RAT		IC50	9.30	CHEMBL
5-hydroxytryptamine receptor 2A	GPCR		5HT2A_RAT		IC50	5.82	CHEMBL
5-hydroxytryptamine receptor 7	GPCR		5HT7R_RAT		IC50	5.52	CHEMBL
Acetylcholinesterase	Enzyme		ACES_RAT		IC50	4.67	CHEMBL
5-hydroxytryptamine receptor 2C	GPCR		5HT2C_RAT		IC50	5.70	CHEMBL
5-hydroxytryptamine receptor 4	GPCR		5HT4R_RAT		IC50	6.60	CHEMBL
D(3) dopamine receptor	GPCR		DRD3_RAT		IC50	7.15	CHEMBL
5-hydroxytryptamine receptor 1D	GPCR		5HT1D_RAT		IC50	5.40	CHEMBL
D(4) dopamine receptor	GPCR		DRD4_RAT		IC50	5.47	CHEMBL
5-hydroxytryptamine receptor 6	GPCR		5HT6R_RAT		IC50	5.52	CHEMBL
Serotonin 3 (5-HT3) receptor	Ion channel		5HT3A_RAT 5HT3B_RAT		IC50	5.37	CHEMBL

External reference:

ID	Source
4030483	VUID
N0000182438	NUI
D09698	KEGG_DRUG
163521-08-2	SECONDARY_CAS_RN
4030483	VANDF
4030484	VANDF
C1530072	UMLSCUI
CHEBI:70707	CHEBI
YG7	PDB_CHEM_ID
CHEMBL439849	ChEMBL_ID
CHEMBL1615374	ChEMBL_ID
D000069503	MESH_DESCRIPTOR_UI
DB06684	DRUGBANK_ID
7427	IUPHAR_LIGAND_ID
7638	INN_ID
S239O2OOV3	UNII
6918314	PUBCHEM_CID
1086768	RXNORM
179494	MMSL
27744	MMSL
d07740	MMSL
013753	NDDF
013754	NDDF
702837008	SNOMEDCT_US
715638004	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
VIIBRYD	HUMAN PRESCRIPTION DRUG LABEL	1	0456-1110	TABLET	10 mg	ORAL	NDA	32 sections
VIIBRYD	HUMAN PRESCRIPTION DRUG LABEL	1	0456-1120	TABLET	20 mg	ORAL	NDA	32 sections
VIIBRYD	HUMAN PRESCRIPTION DRUG LABEL	1	0456-1140	TABLET	40 mg	ORAL	NDA	32 sections
Vilazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0480-2043	TABLET, FILM COATED	40 mg	ORAL	ANDA	29 sections
Vilazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0480-2044	TABLET, FILM COATED	20 mg	ORAL	ANDA	29 sections
Vilazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0480-2045	TABLET, FILM COATED	10 mg	ORAL	ANDA	29 sections
Vilazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16729-352	TABLET	10 mg	ORAL	ANDA	32 sections
Vilazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16729-353	TABLET	20 mg	ORAL	ANDA	32 sections
Vilazodone Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16729-354	TABLET	40 mg	ORAL	ANDA	32 sections
VIIBRYD	HUMAN PRESCRIPTION DRUG LABEL	1	55154-4624	TABLET	40 mg	ORAL	NDA	29 sections
VIIBRYD	HUMAN PRESCRIPTION DRUG LABEL	1	55154-4627	TABLET	20 mg	ORAL	NDA	29 sections
vilazodone	HUMAN PRESCRIPTION DRUG LABEL	1	60505-4772	TABLET	10 mg	ORAL	NDA authorized generic	31 sections
Vilazodone	HUMAN PRESCRIPTION DRUG LABEL	1	60505-4773	TABLET	20 mg	ORAL	NDA authorized generic	31 sections
Vilazodone	HUMAN PRESCRIPTION DRUG LABEL	1	60505-4774	TABLET	40 mg	ORAL	NDA authorized generic	31 sections
VILAZODONE HYDROCHLORIDE	Human Prescription Drug Label	1	62332-232	TABLET, FILM COATED	10 mg	ORAL	ANDA	31 sections
VILAZODONE HYDROCHLORIDE	Human Prescription Drug Label	1	62332-233	TABLET, FILM COATED	20 mg	ORAL	ANDA	31 sections
VILAZODONE HYDROCHLORIDE	Human Prescription Drug Label	1	62332-234	TABLET, FILM COATED	40 mg	ORAL	ANDA	31 sections